Rexahn Pharmaceuticals Inc (NYSE American:RNN)

1.60
Delayed Data
As of 12:34pm ET
 +0.05 / +3.23%
Today’s Change
1.42
Today|||52-Week Range
4.84
-20.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$52.7M

Company Description

Rexahn Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It dedicates to the discovery, development and commercialization of innovative treatments for cancer and other medical needs. The firm have three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin and a robust pipeline of preclinical compounds to treat multiple types of cancer. It has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D gold and times. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Contact Information

Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Rockville Maryland 20850
P:(240) 268-5300
Investor Relations:

Employees

Shareholders

Mutual fund holders4.39%
Other institutional0.74%
Individual stakeholders0.08%

Top Executives

Peter David SuzdakChief Executive Officer & Director
Douglas J. SwirskyPresident & Chief Financial Officer
Ely BenaimChief Medical Officer
Lisa M. NolanChief Business Officer